dihexa raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-01-16 and is reviewed periodically as new material appears.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
| Property | Value | Notes |
|---|---|---|
| Primary proposed target | HGF/c-Met signaling | Direct binding not confirmed |
| Research models | Rodent and cell studies | Preclinical only |
| Human clinical data | None published | Safety and efficacy unknown |
| Regulatory status | Unapproved research chemical | Status varies by country |
| Typical research purity | 95% or higher by HPLC | Depends on supplier and batch |
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
== History == Polatuzumab vedotin was discovered by a team at Genentech led by Dan Eaton, Fred de Sauvage, and Andy Polson, who had been trying to develop ADCs for solid tumors without success, and in 2002 turned to blood cancers. In June 2019, polatuzumab vedotin was approved in the United States in combination with the chemotherapy bendamustine and a rituximab product, to treat adults with diffuse large B-cell lymphoma (DLBCL) that has progressed or returned after at least two prior therapies. Polatuzumab vedotin is a novel antibody-drug conjugate, and DLBCL is the most common type of non-Hodgkin lymphoma. The US Food and Drug Administration (FDA) granted accelerated approval to polatuzumab vedotin used in combination with the chemotherapy bendamustine and a rituximab product. The FDA approved polatuzumab vedotin based primarily on evidence from one clinical trial (NCT02257567) that was conducted in the United States, Canada, Europe, and Asia. Participants in the trial had lymphoma that came back or did not improve after prior treatment. The FDA granted the application of polatuzumab vedotin breakthrough therapy, priority review, and orphan drug designations. The FDA granted the approval of Polivy to Genentech. Polatuzumab vedotin was approved for medical use in the European Union in January 2020, as a second-line treatment. The European Medicines Agency (EMA) designated polatuzumab vedotin an orphan medicine in April 2018.
== Research and development == Simcyp's R&D activities focus on the development of algorithms along with population and drug databases for modelling and simulation (M&S) of the absorption and disposition of drugs in patients and specific subgroups of patients across different age ranges. The Simcyp models use experimental data generated routinely during pre-clinical drug discovery and development from in vitro enzyme and cellular systems, as well as any relevant physico-chemical attributes of the drug and dosage forms. Some details of the scientific background of Simcyp approaches can be found in recent publications.
Photothermal therapy (PTT) is a form of phototherapy that uses non-toxic compounds called photothermal agents (PTA) that, when irradiated at a certain wavelength of light, converts the light energy directly to heat energy. The photothermal conversion efficiency determines the amount of light converted to heat, which can dictate the necessary irradiation time and/or laser intensity for treatments. Typically PTT treatments use wavelengths in the near-infrared (NIR) spectra, which can be further divided into NIR-I (760-900 nm), NIR-II (900-1880 nm), and NIR-III (2080-2340 nm) windows. Wavelengths in these regions are typically less phototoxic than UV or high-energy visible light. In addition, NIR-II wavelengths have been observed to show deeper penetration than NIR-I wavelengths, allowing for treatment of deeper wounds, infections, and cancers. Important considerations for the development of a PTA include photothermal conversion efficiency, phototoxicity, laser intensity, irradiation time, and the temperature at which human cell viability is impaired (around 46-60 °C). Currently, the only FDA-approved photothermal agent is indocyanine green which is active against both tumor and bacterial cells. PTT is less selective than photodynamic therapy (PDT, see above) due to its heat-based mechanism of action, but also less likely to promote drug resistance than most, if not all, currently developed treatments. In addition, PTT can be used in hypoxic environments and on deeper wounds, infections, and tumors than PDT due to the higher wavelength of light.
Despite being offered at other major Canadian restaurant chains, poutine (largely seen as Canada's signature dish), had never been a regular menu item at Tim Hortons. In June 2018, Tim Hortons introduced a limited time poutine across Canada, using seasoned potato wedges instead of the typical French fries. The poutine received mixed responses on social media. In Canada, the company began to offer hamburgers on the lunch menu in 2017. In an attempt to attract customers with a healthier option, Tim Hortons offered a hamburger filled with the "Beyond Meat" meatless option. The offering of hamburgers was risky for the company in their attempt to compete with the popular, large hamburger chains such as McDonald's. Wendy's and Burger King in Canada. Ironically, Burger King had acquired Tim Hortons in 2014 and was running it as a separate subsidiary and had supply chain mechanisms already in place to supply Tim Hortons with hamburger items. However, after only a brief period, consumers did not respond well to Tim Hortons offering of hamburgers or the "Beyond Meat" variety. With poor national sales, subsequently in 2019, hamburgers were removed from the menus at the Canadian Tim Horton's stores. On April 17, 2024, Tim Hortons introduced flatbread pizzas to expand on their lunch/dinner menu. The pizzas are available in four flavours: bacon everything, chicken parmesan, pepperoni, and simply cheese. The fifth flavour Spicy Rosé was introduced in October 2024.
While meeting with British prime minister Keir Starmer in February 2025, Trump accepted a request from King Charles III for a state visit in the U.K.; both Trump and Starmer praised the U.S.–U.K. "Special Relationship". The state visit occurred between September 16–18, 2025. Relations became strained in March 2026 due to Starmer's refusal to join the U.S.–Israeli strikes on Iran during the 2026 Iran war or support the U.S. naval blockade of Iran, prompting Trump to repeatedly condemn the prime minister. King Charles III undertook a state visit to the United States between April 27–30, 2026 and addressed Congress, aimed partly at alleviating these tensions.
Sources: en.wikipedia.org
=== Acute === Acute inflammation is a short-term process, usually appearing within a few minutes or hours and beginning to cease upon the removal of the injurious stimulus. It involves a coordinated and systemic mobilization response of various immune, endocrine and neurological mediators of acute inflammation. In a normal healthy response, it becomes activated, clears the pathogen and begins a repair process and then ceases. Acute inflammation occurs immediately upon injury, lasting only a few days. Cytokines and chemokines promote the migration of neutrophils and macrophages to the site of inflammation. Pathogens, allergens, toxins, burns, and frostbite are some of the typical causes of acute inflammation. Toll-like receptors (TLRs) recognize microbial pathogens. Acute inflammation can be a defensive mechanism to protect tissues against injury. Inflammation lasting 2–6 weeks is designated subacute inflammation.
=== Aftermarket TPMS === Aftermarket TPMS systems are designed to be retrofitted to vehicles that were not originally equipped with the technology. These systems are available for a wide range of vehicles, from bicycles and trailers to heavy-duty trucks. In commercial fleets, aftermarket TPMS are used as part of fleet digitalization. The sensors on each tire wirelessly transmit real-time pressure and temperature data to a GPS tracking unit in the vehicle. This data is then relayed to a fleet management software platform, allowing fleet managers to remotely monitor tire health, receive alerts for under-inflation, and help prevent blowouts or excessive fuel consumption.
"Cooks in the early Navy were left to their own imaginations when it came to preparing meals. In the main, this resulted in whatever was on the official ration for that day of the week being tossed in a ship's coppers and boiled until meal time. The first official Navy cook book was produced by Paymaster F. T. Arms and published by the Bureau of Supplies and Accounts in 1902. It contained five recipes for soup, six for fish, thirty-four for meats, fowl, and eggs, and several for desserts, including "plum duff"."
=== EC 2.1.3: Carboxy- and Carbamoyltransferases === EC 2.1.3.1: methylmalonyl-CoA carboxytransferase EC 2.1.3.2: aspartate carbamoyltransferase EC 2.1.3.3: ornithine carbamoyltransferase EC 2.1.3.4: deleted EC 2.1.3.5: oxamate carbamoyltransferase EC 2.1.3.6: putrescine carbamoyltransferase EC 2.1.3.7: 3-hydroxymethylcephem carbamoyltransferase EC 2.1.3.8: lysine carbamoyltransferase EC 2.1.3.9: N-acetylornithine carbamoyltransferase EC 2.1.3.10: malonyl-S-ACP:biotin-protein carboxyltransferase EC 2.1.3.11: N-succinylornithine carbamoyltransferase EC 2.1.3.13: The enzyme has been replaced by EC 6.1.2.2 EC 2.1.3.14: The enzyme has been replaced by EC 6.1.2.2 EC 2.1.3.15: acetyl-CoA carboxytransferase
=== Johanna Bauer === Princess Johanna Bauer (Susanne Wuest) is the mother of Moritz Hunter-Bauer, heir to the family-owned Austrian bank IBN Bauer, with whom Tender is pursuing a merger. Yasmin, Henry and Whitney visit the Bauers' castle in Vienna to sway Moritz, who opposes the merger due to both data privacy concerns and his fascist political and economic beliefs. While on a walk with Johanna, Yasmin makes a deal to allow Moritz to publish his views in one of Lord Norton's columns in exchange for his backing the merger. Yasmin later finds one of Adolf Hitler's paintings in the room Johanna gave her to stay, confirming earlier rumors of the Bauers' ties to the Third Reich. Johanna and Moritz later attend Yasmin's fundraiser dinner in Paris for far-right MP Sebastian Stefanowicz. She and Moritz are seated beside Harper, to whom they make several racist innuendos.
Sources: en.wikipedia.org
Concessions included not requiring businesses to accept bitcoin as payment, not accepting bitcoin as tax payments, and reducing the number of bitcoins the government was purchasing. The day after the loan was approved, Stacy Herbert, the director of the National Bitcoin Office, stated that El Salvador would continue to buy bitcoins at an "accelerated rate" ("ritmo acelerado") and the government purchased 11 bitcoins then worth over $1 million in total. On 29 January 2025, the Salvadoran government amended the Bitcoin Law to remove bitcoin's status as legal tender and currency but still allows its use as payment. In March 2025, The Economist wrote that El Salvador's bitcoin experiment had been a failure, bringing more costs than benefits to the Salvadoran economy. In 2025, the Salvadoran economy strengthened to 3.9% GDP growth from 2.6 the previous year with private investment growing 36%.
In May 2006, Valve announced a trilogy of episodic games that would continue the story of Half-Life 2 (2004). Episode One was released in 2006, followed by Episode Two in 2007. Episode Three was initially announced for Christmas 2007 and was highly anticipated. Valve released little information in the following years, and in 2011 Wired described it as vaporware. Valve canceled Episode Three as they had become fatigued with Half-Life and struggled to identify new gameplay mechanics. They eventually abandoned episodic development, as they wanted to create more ambitious games. Additionally, as developing Half-Life 2 and the original Source game engine simultaneously had created problems, Valve delayed development of a new Half-Life until their new engine, Source 2, was complete. In 2017, the Half-Life writer, Marc Laidlaw, released a short story that journalists speculated was a summary of the Episode Three plot. In 2024, Valve released footage and concept art of Episode Three as part of a documentary about the making of Half-Life 2.
The hypothalamus uses thyrotropin-releasing hormone (TRH or thyroliberin) to tell the pituitary to release thyrotropin. The hypothalamus uses corticotropin-releasing hormone (CRH or corticoliberin) to tell the pituitary to release corticotropin. The hypothalamus uses gonadotropin-releasing hormone (GnRH or gonadoliberin) to tell the pituitary to release gonadotropin. The hypothalamus uses growth hormone–releasing hormone (GHRH or somatoliberin) to tell the pituitary to release somatotropin. The main release-inhibiting hormones or inhibiting hormones are as follows:
The Inhibition Test procedure does not use zero time light readings and therefore, can not use a correction factor for the timed light level readings. Both of these tests consists of five controls and five replicates of the sample at a single concentration.
Sources: en.wikipedia.org
Dihexa has been proposed to act through HGF and c-Met signaling. This pathway is linked to synapse formation and cellular growth. Direct binding and the precise molecular step remain uncertain.
No published human clinical trials are available for dihexa. Its safety and effectiveness in people are therefore unknown. Most available evidence comes from animal and cell studies.
Preclinical studies often measure dendritic spine density and synaptic protein levels. Behavioral tests include maze learning and avoidance tasks. These endpoints are indirect and do not establish clinical benefit.
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.